Search tips
Search criteria 


Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Clin Pathol. 1997 November; 50(11): 965–967.
PMCID: PMC500328

Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.


A case is reported of a 21 year old woman who suffered from Castleman's disease and systemic reactive amyloidosis. The serum concentrations of serum amyloid A (SAA) and interleukin 6 (IL-6) were extremely high and amyloid protein was immunohistochemically identified as AA. After surgical excision of a large retroperitoneal lymph node with the pathological findings of plasma cell type of Castleman's disease, both serum SAA and IL-6 declined, showing a similar pattern of reduction curves. All clinical symptoms and laboratory abnormalities greatly improved. The biochemical feature of Castleman's disease is abnormal production of IL-6 and this cytokine continuously may stimulate the synthesis of an amyloid precursor, SAA, causing systemic reactive (AA) amyloidosis. This pathogenetic theory is strongly supported by the present study.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (736K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J, Illingworth JM, Perren TJ, Selby PJ, Whicher JT. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol. 1995 Oct;102(1):217–223. [PubMed]
  • Chan WC, Hargreaves H, Keller J. Giant lymph node hyperplasia with unusual clinicopathologic features. Cancer. 1984 May 15;53(10):2135–2139. [PubMed]
  • Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985 Sep;3(9):1202–1216. [PubMed]
  • Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989 Sep;74(4):1360–1367. [PubMed]
  • Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994 Mar 3;330(9):602–605. [PubMed]
  • Ordi J, Grau JM, Junqué A, Nomdedeu B, Palacin A, Cardesa A. Secondary (AA) amyloidosis associated with Castleman's disease. Report of two cases and review of the literature. Am J Clin Pathol. 1993 Oct;100(4):394–397. [PubMed]
  • Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, Marinone MG, Merlini G. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol. 1994 Jul;46(3):189–193. [PubMed]
  • Kazes I, Deray G, Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med. 1995 Mar 1;122(5):395–396. [PubMed]
  • Castell JV, Gómez-Lechón MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988 May 23;232(2):347–350. [PubMed]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group